Completed PHASE1 INTERVENTIONAL 3-arm NCT00329589

A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and Neck, and Cervical Cancer Patients

A Phase I Open-labeled, Dose-escalation, Safety Study of the Combination of Velcade and Chemoradiation for the Treatment of Cancer Patients

Sponsor: Millennium Pharmaceuticals, Inc.

Conditions Brain Cancer Central Nervous System Neoplasms Cervix Cancer Head and Neck Cancer

Interventions Velcade (bortezomib)

Updated 8 times since 2017 Last updated: May 1, 2025 Started: Sep 30, 2005 Primary completion: Jun 30, 2010 Completion: Jun 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Brain Cancer and Central Nervous System Neoplasms and is currently completed. Millennium Pharmaceuticals, Inc. leads this study, which shows 8 recorded versions since 2005 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

8 versions recorded

Feb 2026 — Present [monthly]

Completed PHASE1
Jun 2025 — Feb 2026 [monthly]

Completed PHASE1
Sep 2024 — Jun 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jul 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Jul 2017 [monthly]

Completed PHASE1

First recorded

Sep 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Millennium Pharmaceuticals, Inc.
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Data source: Thomas Jefferson University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Philadelphia, United States